Other meanings of Targeted alpha therapy
Oncology
Targeted alpha therapy is cancer treatment using alpha-emitting radionuclides attached to, or incorporated into, molecules that seek tumor cells. Alpha particles deposit very high energy over only a few cell diameters, producing difficult-to-repair DNA damage while potentially limiting irradiation of nearby normal tissue.1
Targeted alpha therapy works by bringing an alpha-emitting atom close to malignant cells. Alpha particles are helium nuclei with a +2 charge; their short path and high linear energy transfer cause dense clusters of DNA lesions, including double-strand breaks, that can kill cells even when they are resistant to some conventional treatments.1
A targeting component may be a monoclonal antibody, peptide, small molecule, or naturally bone-seeking element. The radionuclide must also have suitable half-life, chemistry, daughter products, and supply characteristics. Commonly studied choices include actinium-225, astatine-211, bismuth-213, lead-212, and thorium-227; each presents a different balance between range, decay timing, labeling chemistry, and radiation protection.
The established clinical example is radium-223 dichloride, which imitates calcium and accumulates in areas of increased bone turnover. The U.S. Food and Drug Administration approved it for men with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease; the treatment improved overall survival in its pivotal trial and reduced symptomatic skeletal events.23
Most other applications remain investigational or are available through regulated clinical programs. Actinium-225 compounds directed at prostate-specific membrane antigen, somatostatin receptors, or other tumor markers have shown responses in early studies, but treatment selection, dosimetry, manufacturing, and comparative evidence are still developing.4
Administration requires radiopharmaceutical production, quality control, patient selection, and radiation-safety procedures. Depending on the agent, clinicians monitor blood counts, renal and hepatic function, tumor response, and delayed toxicity. Radium-223 can cause myelosuppression, gastrointestinal symptoms, and fractures; combining it with abiraterone and prednisone or prednisolone increased fracture and death risk in a randomized study, leading to a contraindication for that combination in the FDA label.2
Targeting is not absolute: blood, kidneys, salivary glands, marrow, and other tissues may receive radiation, while heterogeneous target expression can leave resistant tumor cells untreated. Alpha-emitting daughters may also migrate from the original site. Short range is therefore both an advantage and a limitation, making delivery to every relevant tumor cell essential.
Targeted alpha therapy is constrained as much by nuclear logistics as by oncology. Actinium-225 has a roughly 10-day half-life and a decay chain that produces several alpha emissions, while astatine-211 has a half-life of about 7.2 hours; these properties affect shipping, preparation, and the time available for tumor uptake.14
Radium-223 is unusual because it does not need an antibody or peptide: its calcium-mimicking chemistry directs it to mineralizing bone. By contrast, molecularly targeted agents can reach soft-tissue disease but may require elaborate chelation and protection from daughter-nuclide recoil. Research also addresses fractionated dosing, combination with DNA-repair inhibitors or immunotherapy, and patient-specific dosimetry, while long-term risks such as marrow injury and secondary malignancy remain central to follow-up.
Clinical availability and regulatory status vary by jurisdiction; investigational agents should be distinguished from approved treatments.
Help improve the encyclopedia. Reports go straight to the site manager.